IP Group H1 2026 slides: NAV rises 3% as cash exits surge

IP Group reported H1 2026 NAV per share of 114p, rising to approximately 117p by September 11 from 110p at FY2025-end, while total NAV exceeded £1 billion at £1.006 billion. Cash realizations more than doubled year-on-year to £69 million, lifting gross cash to £238.9 million and net cash to £119.1 million; cumulative exits since January 2025 reached £154 million toward a £250 million end-2027 target. Pfizer obesity-programme exposure added £27 million of fair value to £152 million, while Oxford Nanopore improved gross margin by 400bps to 62.2% and more than halved its adjusted EBITDA loss to £22.1 million.

Analysis

IP Group’s investable feature is not the NAV increase but the potential conversion of a persistent holding-company discount into cash-backed value. At the quoted share price, the implied discount to the latest NAV estimate is roughly 41%, leaving substantial upside if realizations, buybacks, or third-party marks validate carrying values. The discount can remain structurally wide, however: a large portion of NAV is Level-3/private-asset valuation, and the largest upside contributors are concentrated in clinical-development and pre-profit technology exposures rather than recurring cash-generative assets.

The key second-order issue is that cash exits improve optionality but also raise the capital-allocation hurdle. If management recycles proceeds into early-stage assets before demonstrating repeatable shareholder distributions, the market is likely to capitalize the portfolio at a continued 35-45% discount; deploying the authorized repurchase capacity or reducing debt would be more discount-accretive. The expanding external-fund platform could eventually improve fee-related earnings and reduce dependence on balance-sheet gains, but this is a 12-24 month thesis and requires evidence that new vehicles attract durable third-party commitments.

Pfizer and Oxford Nanopore are better viewed as mark-risk concentrations than independent reasons to own IP Group. A clinical delay, weaker obesity differentiation, or a lower peer multiple for listed genomics companies could erase a meaningful portion of reported NAV without a corresponding cash event. Conversely, further realization at or above carrying value over the next 1-3 months is the cleanest near-term catalyst because it directly challenges the market’s skepticism of reported marks. The article’s inconsistent clinical-stage descriptions also argue against underwriting full value to the royalty asset without underlying program verification.

Contrarian view: the discount is sufficiently large that investors do not need all portfolio assets to work, but the catalyst is governance and capital-return discipline—not another paper valuation uplift. This favors IP Group over direct PFE exposure: any obesity-franchise success is immaterial to PFE’s consolidated valuation, whereas it can materially affect IP Group NAV; the reverse is also true for development setbacks.

Key Decisions for Investors

• Initiate a 6-12 month long in LON:IPO only on confirmation that the market price remains at a 35%+ discount to reported NAV; target a 25-30% share-price gain from partial discount closure, with downside limited by reassessed NAV and cash coverage. Exit if NAV per share declines for two consecutive reporting periods or management resumes material net deployment without offsetting buybacks/debt reduction.
• Treat the next disclosed exit as a catalyst trade: add to IPO if a realization is completed at or above its prior carrying value and proceeds are earmarked for repurchases or balance-sheet improvement. Do not add merely on private-company funding rounds, which validate financing access but not exit valuation.
• For liquid exposure to the operating turnaround, prefer a separate small long in LON:ONT rather than assuming IPO’s discount will transmit Oxford Nanopore’s operational progress. Reassess after the next results: sustained gross-margin progress and unchanged path to EBITDA breakeven support the thesis; renewed revenue-guidance cuts or widening cash burn falsify it.
• Avoid a directional PFE trade based solely on the royalty-program narrative. Establish an internal alert for independently confirmed late-stage efficacy, tolerability, and commercial differentiation versus LLY/NVO-class obesity therapies; absent this, the appropriate valuation is a probability-weighted IP Group asset rather than a PFE earnings catalyst.